🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#HSPC to #mCRPC: Management current approaches and future developments. Cookson, Michael & Dr. Jason Efstathiou join Zach Klaassen to discuss advances and future directions in advanced prostate cancer management. #WatchNow on UroToday > bit.ly/44bLEUF

International validation of #AI tool for stratifying #BladderCancer progression risk. Jethro Kwong Univ of Toronto Urology joins Zach Klaassen Georgia Cancer Center to discuss the development and validation of PROGRxN-BCa, an AI model for predicting progression in #NMIBC. #WatchNow >

Optimizing prostate biopsy specimens for improved pathological diagnosis. Improving prostate biopsy accuracy starts with quality tissue samples! #Pathologist Daniel Wiener joins Zach Klaassen Georgia Cancer Center to discuss common challenges and how innovative solutions like URO-1's

Complete response in low-grade #UTUC with padeliporfin therapy in the #ENLIGHTED trial. Vitaly Margulis, MD UT Southwestern Medical Center joins Zach Klaassen Georgia Cancer Center emphasizing that while low-grade upper tract tumors rarely kill patients, they often cost kidneys in a vulnerable

Multicenter European trial investigates gem/doce for #NMIBC. Pietro Scilipoti Ospedale San Raffaele joins Zach Klaassen Georgia Cancer Center sharing European real-world data on gem/doce for BCG-unresponsive NMIBC: 79% HG disease-free survival and 95% 1-yr PFS with excellent tolerability. A

Real-world treatment patterns in advanced #ProstateCancer from #PRECISION data platform. Oliver Sartor, MD Mayo Clinic sits down with Zach Klaassen Georgia Cancer Center, highlighting the registry's value in providing real-world snapshots of evolving treatment patterns in the

#EMBARK subgroup analysis: Enzalutamide monotherapy effective regardless of prior definitive therapy. Stephen Freedland, MD Cedars-Sinai joins Zach Klaassen Georgia Cancer Center sharing EMBARK subgroup data showing enzalutamide monotherapy improves outcomes in high-risk BCR regardless of

Advancing imaging techniques for small renal mass diagnosis and clinical decision-making. Sam S. Chang MD, MBA Vanderbilt Urology joins Zach Klaassen Georgia Cancer Center to discuss the #ZIRCON trial, which highlights a novel PET-CT imaging modality targeting carbonic anhydrase IX (CAIX) for

Real-world data on treatment patterns after PSMA-targeted therapy in #mCRPC. Oliver Sartor, MD Mayo Clinic joins Zach Klaassen Georgia Cancer Center to discuss findings from the #PRECISION data platform examining treatments after Lutetium-617 radioligand therapy. #WatchNow >

Genomic and clinical profiles of rapidly progressing #mCRPC patients. Maha Hussain, MD Lurie Cancer Center joins Zach Klaassen Georgia Cancer Center to discuss a study examining patients who rapidly progress to metastatic castration-resistant #ProstateCancer despite treatment intensification.

#GUOncology Early Thought Leaders conference provides career development beyond clinical training. Elizabeth Plimack MD Fox Chase Cancer Center joins Zach Klaassen Georgia Cancer Center to discuss the importance of this unique event that addresses critical career development topics not typically

#EMBARK Trial: Treatment options for high-risk biochemical recurrence. Neal Shore, MD, FACS CURC and Zach Klaassen Georgia Cancer Center discuss treatment options for high-risk biochemical recurrence following prostatectomy and salvage radiation, using a case presentation of a

Optimizing multidisciplinary care for metastatic hormone-sensitive #ProstateCancer. Zach Klaassen Georgia Cancer Center joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to discuss optimizing #mHSPC care through treatment intensification + multidisciplinary teamwork. Despite proven benefits, many still

Long-term results of N-803 + BCG for BCG-unresponsive #BladderCancer. Sam S. Chang MD, MBA Vanderbilt Urology joins Zach Klaassen Georgia Cancer Center to discuss updates on N-803, long-term data with median follow-up now exceeding 2.5 years, showing a complete response rate of 71% in the CIS

Optimal treatment strategies for de novo metastatic hormone-sensitive #ProstateCancer. Neal Shore, MD, FACS CURC joins Zach Klaassen Georgia Cancer Center in a case-based discussion of a 67-year-old man with significant comorbidities including renal insufficiency, cardiac history,

Apalutamide vs Enzalutamide: Racial Disparities in #mCSPC Treatment Outcomes. Ben Lowentritt Chesapeake Urology joins Zach Klaassen Georgia Cancer Center to discuss real-world outcomes comparing apalutamide vs enzalutamide in Black patients with metastatic hormone-sensitive #ProstateCancer.

SASAN-SPARING trial: Bladder-sparing approach for muscle-invasive #BladderCancer. Elena Sevillano M.D. PhD joins Zach Klaassen Georgia Cancer Center to discuss alternatives to radical cystectomy given its significant impact on patients' urinary, bowel, and sexual function, noting that some patients

Advancing #microhematuria evaluation: The impact of urinary biomarkers and updated guidelines. Jay Raman Penn State Health & yair lotan UT Southwestern Medical Center sit down with Zach Klaassen Georgia Cancer Center, breaking down the latest in microhematuria evaluation — from 2020–2025 guidelines, to

Comparing industry-sponsored and investigator-initiated trials in genitourinary oncology. KSridhar Princess Margaret Cancer Centre joins Zach Klaassen Georgia Cancer Center sharing findings from the analysis of nearly 6,000 trials between 2007-2021, highlighting that while distribution was initially

The details are in the core: Advancing prostate tissue collection. James Wysock NYU Langone Health joins Zach Klaassen Georgia Cancer Center to discuss improving prostate cancer diagnostics through better biopsy needle technology, highlighting early experience with the SUREcore® Biopsy Needle from